State of the art of perioperative assessment in early non-small-cell lung cancer in Poland in the emerging era of perioperative protocols
@tamedoncol.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cancertreatment #NSCLC #oncology #openaccess

TACTI-004 Trial Set to Be Discontinued Following Futility Analysis in NSCLC | OncLive The phase 3 TACTI-004 trial has been discontinued in patients with NSCLC in accordance with an independent data monitoring committee recommendation.

The phase 3 TACTI-004 trial has been discontinued in patients with NSCLC in accordance with an independent data monitoring committee recommendation. #oncology #lcsm #nsclc
Read more here: www.onclive.com/view/tacti-0...

Drs. Mikkel G. Terp, Grith Lykke Sorensen, and team at @sdu.dk demonstrate that the SP-D gene expression is reduced to near absence in metastatic #NSCLC tissue, linking its loss to metastatic progression.

https://go.nature.com/4ruMpk1

🔷 The study explores whether this combination strategy can offer improved clinical outcomes compared with standard immunotherapy alone.

🔗 Read more: bit.ly/ONCOnews-11M...

#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC #CancerResearch #Oncology #Immunotherapy #CancerTreatment #ClinicalTrials

Elizabeth McKenna: New ELIOS Study on EGFR-Mutant NSCLC - OncoDaily Elizabeth McKenna: New ELIOS Study on EGFR-Mutant NSCLC / Aleksandra Markovets, Byoung Chul Cho, cancer, Cancer Discovery, Delvys Rodriguez Abreu, Diego

New ELIOS Study on EGFR-Mutant NSCLC - Elizabeth McKenna

@elizsmckenna.bsky.social @aacrjournals.bsky.social

oncodaily.com/voices/eliza...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC

Medical office waiting room

In for maintenance on my vocal cord. Gonna lose my actual voice for a few days. Guess that means more writing. #cancerlife #ALKPositive #NSCLC

The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 DAY FIVE
Presentation by Dr. Gilberto Lopes🇺🇸 : Year in Review Early #NSCLC
WATCH NOW, NO REGISTRATION👉 www.oncoalert360.com/2026-oncoale...

Practice-changing research in 2025 in early NSCLC 🚀

Stephen V Liu: Neoadjuvant vs Perioperative Immunotherapy in NSCLC at NYLCF26 - OncoDaily Stephen V Liu: Neoadjuvant vs Perioperative Immunotherapy in NSCLC at NYLCF26 / cancer, NSCLC, NYLCF26, OncoDaily, Oncology, Solange Peters, Stephen V Liu

Neoadjuvant vs Perioperative Immunotherapy in NSCLC at NYLCF26 - Stephen V Liu

@stephenvliu.bsky.social

oncodaily.com/voices/steph...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC

GPR54 promotes progression & #MetabolicReprogramming in #NSCLC by enhancing dopa decarboxylase expression via the Gαq/11/PI3K/AKT/mTOR signaling pathway, underscoring its potential as both a #Biomarker & #TherapeuticTarget.

#OpenAccess: doi.org/10.1038/s413...

#machinelearning #NeuralNetworks #Statistics #Python #multiplexed #images #NSCLC #PerkinElmer #vectra #NIH #NCI

Findings from the randomized ATTENTION #ClinicalTrial demonstrate that #Aumolertinib plus #Apatinib significantly improves progression-free survival with manageable safety in treatment-naïve, #EGFR-mutant advanced #NSCLC.

#STTT #OpenAccess: doi.org/10.1038/s413...

NCCN NSCLC Guidelines Update Staging, Emphasize Molecular Testing The National Comprehensive Cancer Network's newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab deruxtecan-dlink a preferred option for some patients in se...

New NCCN Guidelines for #NSCLC emphasize integrated staging and molecular testing. Molecular analysis is mandatory for all nonsquamous NSCLC cases to guide targeted therapy.

Read the review: https://bit.ly/4b28ksw

#MedEd #OncTwitter #LungCancer #LCSM

March Issue: Evaluating Surgical Approaches in Early #NSCLC : A Meta-Analysis of Robot-Assisted and Video-Assisted Techniques

https://rdcu.be/e5I7K

Effects of uniportal #3DVideo assisted #thoracicsurgery lobectomy on postoperative pain and immune function in patients with #NSCLC

journals.sagepub.com/share/K4B5F6...

Three bar graphs compare treatment probability by race (Black, White) over time (2005-2019): A) Any treatment (surgery/radiotherapy); B) Surgery; C) Primary radiotherapy. Each graph displays estimated probability (%) on the y-axis versus the year of diagnosis.

Racial disparities in curative therapy for #NSCLC among Medicare beneficiaries persisted from 2005 to 2019, with limited improvement despite expanded radiotherapy options.

ja.ma/476Srjo

🎯 4 dianas clave.
🧬 Tratamiento de precisión.
🌍 Impacto global.

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#CáncerDePulmón #CáncerDePulmónNoMicrocítico #NSCLC #Oncología #OncologíaClínica #SaludGlobal #EGFR #ALK #PD1 #PDL1 #KRAS #KRASG12C #DengYueMedicinasEnHongKong

💊FDA Approval Update | #HERNEXEOS® (#zongertinib tablets): the first targeted therapy for #HER2 mutant advanced #NSCLC
🔹For adults as an initial treatment option
🔹11% of patients with a complete response
🔹65% of patients with a partial response

Stephen V Liu: Intracranial Efficacy of Trastuzumab Deruxtecan in HER2-Mutant NSCLC - OncoDaily Stephen V Liu: Intracranial Efficacy of Trastuzumab Deruxtecan in HER2-Mutant NSCLC / Achim Rittmeyer, Adrianus de Langen, Akram Saad, Albrecht Stenzinger,

Intracranial Efficacy of Trastuzumab Deruxtecan in HER2-Mutant NSCLC - Stephen Liu

@stephenvliu.bsky.social

oncodaily.com/voices/steph...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC

Zongertinib Approved by FDA for HER2+ NSCLC Zongertinib receives FDA accelerated approval for advanced HER2-mutant NSCLC, expanding targeted treatment options.

Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #NSCLC #MedEd #MedOnc #MedNews #LungCancer #HER2 #TargetedTherapy #FDAApproval

FDA 🇺🇸 grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer #NSCLC 🫁

www.fda.gov/drugs/resour...

On February 26, 2026, the FDA granted accelerated approval to zongertinib in unresectable or metastatic HER2-mutated NSCLC

Findings from a phase II #ClinicalTrial reveal that perioperative #Penpulimab + #Anlotinib provides promising efficacy and a manageable safety profile for resectable #NSCLC, identifying a potent new combination therapy.
#STTT #OpenAccess: doi.org/10.1038/s413...

Radiotherapy Challenges in Locally Advanced Non-Small Cell Lung Cancer in the Neoadjuvant Era | IASLC Stage III NSCLC is now a moving target! This webinar will address key practice gaps and real-world decision points in the radiotherapy management of locally adv ...

Join us for an IASLC webinar!
This session will dive into practical radiotherapy strategies, staging insights, and multimodality care considerations for Stage III NSCLC.

Register here: bit.ly/4tLVFm7

#LungCancer #NSCLC #Oncology #Radiotherapy #MedicalEducation

🚀From Bench to Paper | New research identifies a #microRNA–#RASH3D19 feedback loop that drives #RAS signaling in #KRAS-mutant cancers. Targeting RASH3D19 improves KRAS inhibitor response in #CRC and #NSCLC.
🌟#Sotorasib and #RMC4550 (MedChemExpress) were used in this research.

CStone Secures Historic MHRA Approval for Sugemalimab Treatment in Stage III NSCLC CStone Pharmaceuticals has received new indication approval from the UK MHRA for sugemalimab, aimed at patients with Stage III non-small cell lung cancer, expanding its global reach.

CStone Secures Historic MHRA Approval for Sugemalimab Treatment in Stage III NSCLC #United_Kingdom #N/A #NSCLC #CStone #Sugemalimab

A prospective #NSCLC study shows a multimodal model combining bTMB, ctDNA dynamics, and first RECIST response accurately predicts durable benefit from #ICIs, enabling early #noninvasive identification of responders for personalized #immunotherapy.

#STTT: doi.org/10.1038/s413...

Continued Benefits of Zenocutuzumab Treatment in NRG1+ NSCLC Patients: Insights from the eNRGy Trial The eNRGy trial reveals promising results for zenocutuzumab as a treatment beyond progression in NRG1+ NSCLC patients, showing potential long-term benefits.

Continued Benefits of Zenocutuzumab Treatment in NRG1+ NSCLC Patients: Insights from the eNRGy Trial #United_States #Lexington #NSCLC #Zenocutuzumab #NRG1_Fusion

Register:
give.cancergrace.org/event/lung-c...

Support free patient education — donate today. 💙

#LungCancer #NSCLC #TargetedTherapy

PALOMA-2 #NSCLC 🫁 FDA Approval
NEWS FROM INDUSTRY: Source J&J

The FDA 🇺🇸 approved a simplified once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj from Johnson & Johnson for first-line EGFR-mutated advanced non-small cell lung cancer.

www.jnj.com/media-center...

LIBRETTO-432 Update on #NSCLC 🫁
NEWS FROM INDUSTRY: Source Eli Lilly

lilly.mediaroom.com/2026-02-16-L...

Adjuvant Selpercatinib Improves EFS in Early-Stage RET Fusion–Positive NSCLC | OncLive Improved EFS was seen when selpercatinib was administered as adjuvant therapy vs placebo in early-stage RET fusion–positive NSCLC.

Adjuvant Selpercatinib Improves EFS in Early-Stage RET Fusion–Positive NSCLC #medtwitter #oncology #lcsm #nsclc
www.onclive.com/view/adjuvan...